LONDON: Roquefort Therapeutics (LSE:ROQ), a biotech company focused on developing innovative immunology and oncology medicines, has announced a term sheet agreement for the sale of its subsidiary, Oncogeni Ltd, to The Nations Trust Holding LLC. The deal is valued at up to $12 million in cash, including upfront and milestone payments. Roquefort Therapeutics and Nations…